Key Takeaways
- Forbion’s BioEconomy Fund I has raised €164.5 million, surpassing its initial €150 million target.
- The fund is supported by top institutional investors, including KfW Capital, Novo Holdings, Rentenbank, and Aurae Impact, as well as new backers ABN AMRO Bank and EIFO.
- Launched in November 2023, the fund focuses on biotech solutions for sustainability challenges in Food, Agriculture, Materials, and Environmental Technologies.
- The fund aims to reach its hard cap of €200 million at its final close.
- A core strategy of the fund is achieving price parity with existing solutions to enable large-scale adoption.
Fundraising Milestone For Forbion
Forbion, a leading venture capital firm specializing in biotech in Europe and the US, announced that its BioEconomy Fund I has raised €164.5 million, surpassing its original target of €150 million. The fund, which launched in November 2023, focuses on advancing biotechnology innovations that address global sustainability challenges.
The fund is backed by prominent institutional investors, including KfW Capital, Novo Holdings, Rentenbank, and Aurae Impact, with additional support from new backers ABN AMRO Bank and EIFO. A final close is expected at or near the hard cap of €200 million, reflecting growing confidence in the commercial potential of sustainable biotech solutions.
Focus on Planetary Health
The Forbion BioEconomy Fund I is a planetary health-focused fund targeting business-to-business (B2B) solutions that replace unsustainable products with scalable, cost-effective alternatives. Its strategy centers on ensuring these innovations achieve price parity with existing options, facilitating widespread adoption across its four target sectors:
- Food
- Agriculture
- Materials
- Environmental Technologies
Leadership Statement From Forbion
Commenting on the milestone, Sander Slootweg, Managing Partner and co-founder of Forbion, said: “Exceeding €150 million in just over a year reflects the strength of our team and strategy and the confidence our investors have in our ability to execute. Their support for BioEconomy Fund I demonstrates the growing demand for scalable, cost-competitive biotech solutions that deliver both sustainability and strong returns.”
